复星医药资本运作遭遇一次重大受挫,高负债、高担保问题突出

新浪财经
20 Feb

1月22日, 复星医药 (600196.SH,02196.HK)公告称,拟私有化旗下子公司 复宏汉霖 (2696.HK)的计划未能获得独立H股股东的批准,导致复宏汉霖将继续保持H股上市地位。这一失败标志着复星医药在资本运作上的一次重大受挫,也暴露出其在整合资源、优化资产结构方面的挑战。复星医药原计划通过54.07亿港元的收购方案,以现金或换股方式将复宏汉霖私有化,并以每股24.60港元的价格收购...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10